Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daplusiran/tomligisiran - GSK

Next Previous
Drug Profile

Daplusiran/tomligisiran - GSK

Alternative Names: ARO-HBV; GSK-5637608; JNJ-3989; JNJ-73763989

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Developer Arrowhead Pharmaceuticals; GSK; Janssen Research & Development; Janssen Sciences Ireland UC; Johnson & Johnson Innovative Medicine
  • Class Amino sugars; Antivirals; Drug conjugates; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D

Most Recent Events

  • 05 Mar 2025 Janssen Research & Development completes the phase II REEF-D trial in Hepatitis B and Hepatitis D (Combination therapy) in USA, United Kingdom, Turkey, Taiwan, Sweden, Spain, Russia, Japan, Italy, Germany, France, China, Brazil, Australia, New Zealand (SC) (NCT04535544)
  • 15 Nov 2024 Pharmacodynamics data from a phase IIb trial in Hepatitis B presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
  • 11 Nov 2024 Phase-II clinical trials in Hepatitis B (Treatment-experienced) in United Kingdom, Taiwan, Spain, South Africa, South Africa, Singapore, New Zealand, South Korea, Japan, Italy, Hong Kong, Greece, Germany, France, China, Canada, Brazil, Belgium, Australia (SC) (NCT06537414)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top